Sumitomo Mitsui Ds Asset Management Company, LTD Biogen Inc. Transaction History

Sumitomo Mitsui Ds Asset Management Company, LTD

$9.6 Billion
Q4 2024

A detailed history of Sumitomo Mitsui Ds Asset Management Company, LTD transactions in Biogen Inc. stock. As of the latest transaction made, Sumitomo Mitsui Ds Asset Management Company, LTD holds 17,761 shares of BIIB stock, worth $2.43 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

17,761

Previous 19,702 9.85%

Holding current value

$2.43 Million

Previous $3.82 Million 28.88%

% of portfolio

0.03%

Previous 0.04%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Jan 28, 2025	SELL	$146.47 - $191.55 $284,298 - $371,798	-1,941 Reduced 9.85%	17,761 $2.72 Million
Q3 2024 Oct 17, 2024	BUY	$189.07 - $236.8 $92,455 - $115,795	489 Added 2.55%	19,702 $3.82 Million
Q2 2024 Jul 30, 2024	BUY	$190.52 - $236.72 $289,971 - $360,287	1,522 Added 8.6%	19,213 $4.45 Million
Q1 2024 May 02, 2024	SELL	$212.02 - $267.71 $13,145 - $16,598	-62 Reduced 0.35%	17,691 $3.81 Million
Q4 2023 Feb 01, 2024	SELL	$222.59 - $267.94 $17,807 - $21,435	-80 Reduced 0.45%	17,753 $4.59 Million
Q3 2023 Oct 30, 2023	BUY	$253.3 - $285.89 $251,020 - $283,316	991 Added 5.88%	17,833 $4.58 Million
Q2 2023 Aug 04, 2023	BUY	$275.25 - $318.06 $1.47 Million - $1.69 Million	5,327 Added 46.26%	16,842 $4.8 Million
Q1 2023 May 02, 2023	BUY	$256.56 - $292.34 $39,253 - $44,728	153 Added 1.35%	11,515 $3.2 Million
Q4 2022 Jan 26, 2023	BUY	$252.44 - $306.72 $233,254 - $283,409	924 Added 8.85%	11,362 $0
Q3 2022 Oct 19, 2022	BUY	$194.69 - $268.46 $33,876 - $46,712	174 Added 1.7%	10,438 $2.79 Million
Q2 2022 Jul 13, 2022	BUY	$187.54 - $223.02 $148,719 - $176,854	793 Added 8.37%	10,264 $2.09 Million
Q1 2022 Apr 19, 2022	SELL	$193.77 - $244.14 $7,750 - $9,765	-40 Reduced 0.42%	9,471 $2 Million
Q4 2021 Jan 20, 2022	SELL	$223.92 - $287.77 $2,910 - $3,741	-13 Reduced 0.14%	9,511 $2.28 Million
Q3 2021 Oct 15, 2021	SELL	$282.99 - $369.05 $26,318 - $34,321	-93 Reduced 0.97%	9,524 $2.7 Million
Q2 2021 Jul 19, 2021	SELL	$259.0 - $414.71 $12,432 - $19,906	-48 Reduced 0.5%	9,617 $3.33 Million
Q1 2021 May 07, 2021	SELL	$242.95 - $284.63 $105,926 - $124,098	-436 Reduced 4.32%	9,665 $2.7 Million
Q4 2020 Feb 02, 2021	SELL	$236.26 - $355.63 $120,020 - $180,660	-508 Reduced 4.79%	10,101 $2.47 Million
Q3 2020 Oct 29, 2020	SELL	$264.77 - $305.71 $19,592 - $22,622	-74 Reduced 0.69%	10,609 $3.01 Million
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $46,300 - $61,316	-179 Reduced 1.65%	10,683 $2.86 Million
Q1 2020 Apr 21, 2020	SELL	$268.85 - $341.04 $157,277 - $199,508	-585 Reduced 5.11%	10,862 $3.44 Million
Q4 2019 Jan 24, 2020	SELL	$220.06 - $304.07 $110,250 - $152,339	-501 Reduced 4.19%	11,447 $3.4 Million
Q3 2019 Oct 16, 2019	BUY	$217.44 - $243.88 $174,169 - $195,347	801 Added 7.19%	11,948 $2.78 Million
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $665,983 - $734,103	-3,037 Reduced 21.41%	11,147 $2.61 Million
Q1 2019 May 07, 2019	BUY	$216.71 - $338.96 $153,647 - $240,322	709 Added 5.26%	14,184 $3.35 Million
Q4 2018 Jan 25, 2019	SELL	$278.5 - $352.75 $300,780 - $380,970	-1,080 Reduced 7.42%	13,475 $4.05 Million
Q3 2018 Oct 15, 2018	SELL	$293.51 - $383.83 $34,047 - $44,524	-116 Reduced 0.79%	14,555 $5.14 Million
Q2 2018 Jul 31, 2018	BUY	$257.52 - $306.91 $30,387 - $36,215	118 Added 0.81%	14,671 $4.26 Million
Q1 2018 Apr 25, 2018	SELL	$260.13 - $367.91 $186,253 - $263,423	-716 Reduced 4.69%	14,553 $3.98 Million
Q4 2017 Jan 25, 2018	SELL	$307.64 - $344.58 $392,548 - $439,684	-1,276 Reduced 7.71%	15,269 $4.86 Million
Q3 2017 Oct 27, 2017	BUY	$281.15 - $329.69 $4.65 Million - $5.45 Million	16,545	16,545 $5.18 Million

Others Institutions Holding BIIB

# of Institutions

995

Shares Held

131M

Call Options Held

1.77M

Put Options Held

2.34M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $19.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.

Account

Sumitomo Mitsui Ds Asset Management Company, LTD Biogen Inc. Transaction History